Biocon jumps after biopharma firm inks deal with Brazil-based Biomm SA
Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market, the company said in a statement on Wednesday.
Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments. Photo: File/Representational